Methylene Chloride

Methylene Chloride

SCHEMBL4557546

CC(=O)CC(Cl)Cl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL2391146 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL2456472 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL6704394 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL861591 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL4304807 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL3630221 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL7695098 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL5133360 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL1395290 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL5091282 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118339171-A Novel method for producing compound, novel compound, and metal catalyst 国立研究开发法人科学技术振兴机构 2024-07-12 CN disclosed
EP-4385994-A1 NOVEL METHOD FOR PRODUCING COMPOUND, NOVEL COMPOUND, AND METAL CATALYST Japan Science and Technology Agency (JP) 2024-06-19 EP disclosed
WO-2023017841-A1 NOVEL METHOD FOR PRODUCING COMPOUND, NOVEL COMPOUND, AND METAL CATALYST 国立研究開発法人科学技術振興機構 2023-02-16 WO disclosed
US-7608718-B2 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity SOLVAY PHARMACEUTICALS B.V. (NL) 2009-10-27 US disclosed
US-20070259884-A1 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity SOLVAY PHARMACEUTICALS B.V. 2007-11-08 US disclosed
US-6974810-B2 cannabinoid (cb1); treating disorders involving cannabinoid neurotransmission SOLVAY PHARMACEUTICALS B.V. (NL) 2005-12-13 US disclosed
CN-1529595-A 4, 5-2H-1H-pyrazole derivatives having potent CB 1-antagonistic activity ������ҩ�����޹�˾ 2004-09-15 CN disclosed
EP-1429762-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING POTENT CB1-ANTAGONISTIC ACTIVITY Solvay Pharmaceuticals B.V. (NL) 2004-06-23 EP disclosed
US-20040106800-A1 4,5-Dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity ABBVIE B.V. (NL) 2004-06-03 US disclosed
WO-2003026648-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING POTENT CB1-ANTAGONISTIC ACTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259884-A1 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity CNR1, CNR2, GPR55 ALDH1A1 1410/4885TDP1 4634/4885TRPA1 250/4885
US-20040106800-A1 4,5-Dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity CNR1, CNR2, FAAH ALDH1A1 996/4885TDP1 4313/4885TRPA1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.